ethyl 2-[2-(2-ethoxy-2-oxoethyl)phenyl]acetate | 17532-66-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-[2-(2-ethoxy-2-oxoethyl)phenyl]acetate
• 英文别名: (o-Phenylen)bis(essigsaeure-ethylester)；diethyl benzene-1,2-diacetate；diethyl 1,2-benzenediacetate；o-phenylenedi-acetic acid diethyl ester；o-Phenylendi-essigsaeure-diaethylester；(2-ethoxycarbonylmethyl-phenyl)-acetic acid ethyl ester；1,2-Benzenediacetic acid diethyl ester
• CAS: 17532-66-0
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: GTHDFYARNWTZJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090

反应信息

• 作为反应物：
  描述：

  ethyl 2-[2-(2-ethoxy-2-oxoethyl)phenyl]acetate 在 硫酸 、 sodium 、 甲苯 作用下， 生成 2-茚酮
  参考文献：
  名称：

  Perkin; Titley, Journal of the Chemical Society, 1922, vol. 121, p. 1570

  摘要：

  DOI：
• 作为产物：
  描述：

  乙醇 、 1,2-苯二乙腈 在 硫酸 作用下， 反应 6.0h， 以70.6%的产率得到ethyl 2-[2-(2-ethoxy-2-oxoethyl)phenyl]acetate
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF

  摘要：

  本发明提供了一种三环化合物，其在单个分子中具有受体酪氨酸激酶、二氢叶酸还原酶、胸苷酸合成酶和/或二氢甲氧呋喃脱氢酶的抑制活性，这些化合物具有细胞静止和细胞毒活性，可用作抗血管生成和抗肿瘤药物。还提供了利用这些抑制剂治疗肿瘤细胞和其他增殖性疾病和紊乱的方法。

  公开号：

  US20090062318A1

文献信息

• Preparation of New Dialkyl Benzene-, Biphenyl-, and Naphthalene-bis(α-oxoethanedithioates)
  作者：Jürgen Voss、Abraam Sarafidis、Andrzej Sawluk、Gunther Schmidt、Gunadi Adiwidjaja

  DOI：10.1080/10426500903575409

  日期：2010.10.28

  carbonyl-activated methylene and methyl compounds exhibiting no bromo or diazo substituents could be also transformed into dithioesters by the CAT reaction. The structure of three dithioesters was corroborated by X-ray structural analyses. Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental

  苯、联苯、特别是萘系列的新型芳烃双和三（α-氧代乙烷二硫酸酯）酯是通过相应的重氮乙酰或溴乙酰衍生物与元素硫在三乙胺存在下在干燥条件下反应制备的。 DMF，以及随后产生的二硫代羧酸根阴离子的直接烷基化。添加无水氯化钙（氯化钙活化的硫醇化，或 CAT）可显着促进重氮酮的硫醇化反应。某些没有溴或重氮取代基的羰基活化亚甲基和甲基化合物也可以通过 CAT 反应转化为二硫酯。X 射线结构分析证实了三种二硫酯的结构。补充材料可用于本文。去出版商'
• [EN] INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7<br/>[FR] DÉRIVÉS D'INDANE UTILES EN TANT QUE MODULATEURS DE MGLUR7
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018047983A1

  公开（公告）日：2018-03-15

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X, Y, Z, D, R1, R2, R3, R4, R12, R15nd R16 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use as modulators of mGluR7.

  本发明提供了化合物的公式(I)及其药用盐，其中n、X、Y、Z、D、R1、R2、R3、R4、R12、R15和R16如规范中所定义，以及它们的制备方法、含有它们的药物组合物以及它们作为mGluR7调节剂的用途。
• [EN] MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS<br/>[FR] COMPOSÉS AGONISTES DE MGLUR7 POUR LE TRAITEMENT DE MALADIES, TROUBLES OU ÉTATS RÉGULÉS PAR MGLUR7
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018092921A1

  公开（公告）日：2018-05-24

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

  本发明提供了式(I)的化合物及其药用盐，其中Z、R1、R2、R3、R4、R5和R6如规范中定义，以及它们的制备方法，含有它们的药物组合物以及它们在治疗中的用途。本发明还提供了治疗至少一种与谷氨酸能和GABA能信号通路相关的疾病、紊乱或症状的方法，该信号通路完全或部分由代谢型谷氨酸受体7（mGluR7）调节，通过向受试者投药式(I)的化合物或其药用盐。该化合物可能是mGluR7的选择性激动剂，调节受试者中至少一种神经递质的释放。
• TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF
  申请人：Gangjee Aleem

  公开号：US20090062318A1

  公开（公告）日：2009-03-05

  The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.

  本发明提供了一种三环化合物，其在单个分子中具有受体酪氨酸激酶、二氢叶酸还原酶、胸苷酸合成酶和/或二氢甲氧呋喃脱氢酶的抑制活性，这些化合物具有细胞静止和细胞毒活性，可用作抗血管生成和抗肿瘤药物。还提供了利用这些抑制剂治疗肿瘤细胞和其他增殖性疾病和紊乱的方法。
• MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME
  申请人：TABATA Masayoshi

  公开号：US20110224343A1

  公开（公告）日：2011-09-15

  The present invention provides a modifier for aromatic polyesters which enhances the melt fluidity of aromatic polyesters without a significant decrease in the heat resistance of the aromatic polyesters, and an aromatic polyester resin composition including the modifier for aromatic polyesters. The present invention relates to a modifier for aromatic polyesters comprising polyhydric phenol residues and residues of aromatic polycarboxylic acid, acid halide or acid anhydride thereof, and the modifier comprises a material having a structure composed of a first residue selected from the group consisting of divalent residues represented by Formula (I): —Ar—W 1 x —Ar— and by Formula (II): —Ar—, the first residues being bonded to two identical or different second residues selected from the group consisting of monovalent residues represented by Formula (III): and monovalent residues represented by Formula (IV): —O—C(O)—R 7 —.

  本发明提供了一种用于芳香族聚酯的改性剂，可以增强芳香族聚酯的熔融流动性，而不明显降低芳香族聚酯的耐热性，以及包括该改性剂的芳香族聚酯树脂组合物。本发明涉及一种用于芳香族聚酯的改性剂，包括多羟基酚残基和芳香族多羧酸、酸卤或其酸酐残基，该改性剂包括具有以下结构的材料：第一残基，选择自由式(I)所代表的二价残基：—Ar—W1x—Ar—和自由式(II)所代表的：—Ar—，第一残基与选择自由式(III)所代表的单价残基：和自由式(IV)所代表的单价残基：—O—C(O)—R7—的两个相同或不同的第二残基结合。